Chimeric switch and inverted cytokine receptors in T cell therapy: reprogramming T cells to overcome immune suppression in the solid tumor microenvironment
Frontiers in Immunology · 08.10.2025 · 16
DOI: 10.3389/fimmu.2025.1662238 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 08.10.2025. Verfasst von Riley Rane und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physiology and Biomedical Engineering, Mayo Clinic Arizona, Scottsdale, AZ, United States. Hauptthemen laut MEDLINE: Tumor Microenvironment, Immunotherapy, Adoptive, Neoplasms, T-Lymphocytes. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 86 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Adoptive T cell therapy has transformed cancer treatment, with chimeric antigen receptor (CAR) T cell therapy demonstrating remarkable clinical success in hematological malignancies. By genetically engineering a patient’s own T cells to recognize and attack cancer cells, CAR T therapy has achieved durable remissions in several blood cancers. However, its efficacy in solid tumors remains limited, largely due to the immunosuppressive tumor microenvironment (TME), which impairs T cell infiltration, persistence, and function. To address these challenges, innovative strategies are being developed to reprogram T cell signaling within the hostile TME. One promising class involves chimeric non-antigen receptors (CNARs), which modulate T cell activity independently of direct antigen recognition. Among these, chimeric switch receptors (CSRs) convert inhibitory checkpoint signals into activating cues, while inverted cytokine receptors (ICRs) redirect suppressive cytokine signals to promote T cell activation. In this review, we provide a focused overview of the design principles, mechanistic functions, and therapeutic potentials of CSRs and ICRs as adjuncts to CAR T therapy in solid tumors. We also discuss key considerations regarding safety, specificity, and clinical translation to inform future advancements in engineered receptor strategies for cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Physiology and Biomedical Engineering, Mayo Clinic Arizona, Scottsdale, AZ, United States.
- Department of Immunology, Mayo Clinic Arizona, Scottsdale, AZ, United States.
- Department of Cancer Biology, Mayo Clinic Arizona, Phoenix, AZ, United States.
- Department of Neurological Surgery, Mayo Clinic Arizona, Phoenix, AZ, United States.
- Department of Neurosurgery, University of Maryland School of Medicine, Baltimore, MD, United States.
- Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore, MD, United States.
Zitieren
APA
Rane, R., Li, F., Williams, A., Jayadev, A., Tran, N. L., Winkles, J. A., & Kim, G. B. (2025). Chimeric switch and inverted cytokine receptors in T cell therapy: reprogramming T cells to overcome immune suppression in the solid tumor microenvironment. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1662238
Vancouver
Rane R, Li F, Williams A, Jayadev A, Tran NL, Winkles JA, et al. Chimeric switch and inverted cytokine receptors in T cell therapy: reprogramming T cells to overcome immune suppression in the solid tumor microenvironment. Frontiers in Immunology. 2025;16. doi:10.3389/fimmu.2025.1662238
BibTeX
@article{Rane2025,
author = {Rane, Riley and Li, Fengqiao and Williams, Alexis and Jayadev, Avaneesh and Tran, Nhan L and Winkles, Jeffrey A and Kim, Gloria B},
title = {Chimeric switch and inverted cytokine receptors in T cell therapy: reprogramming T cells to overcome immune suppression in the solid tumor microenvironment},
journal = {Frontiers in Immunology},
year = {2025},
volume = {16},
doi = {10.3389/fimmu.2025.1662238}
}
EUVIMED